This trial is active, not recruiting.

Conditions localized, primary osteoarthritis, post-traumatic arthrosis of other joints, shoulder region, avascular necrosis of the head of humerus
Treatment shoulder hemi-arthroplasty
Sponsor Tornier
Start date April 2011
End date April 2021
Trial size 100 participants
Trial identifier NCT02444299, 0908-T-RESURF-RM


Aequalis® Resurfacing Head implant is a range of shoulder arthroplasty device available for the treatment of various shoulder pathologies. It received CE Mark in June 2007.

The aim of this study is to collect immediate medium and long term data on performance and safety of the implant, retrospectively as well as prospectively, from a consecutive series of patients to assess the patients' outcomes and functional status.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Implant survival rate
time frame: up to 10-year follow-up

Secondary Outcomes

Change from baseline and previous visit in Constant Murley score
time frame: at 3-month, 1, 2, 5, 10 years follow-up
Change from baseline and previous visit in Range Of Motion
time frame: at 3-month, 1, 2, 5, 10 years follow-up
Change from baseline and previous visit in SSV.
time frame: at 3-month, 1, 2, 5, 10 years follow-up

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patient has received an Aequalis® Resurfacing Head implant as per the manufacturer's instructions (including the recommended indication): degenerative indication such as primary osteoarthritis, secondary osteoarthritis (post-traumatic post instability), avascular osteonecrosis of the humeral head ; - with a functional rotator cuff ; - has clinical and radiographic follow-up data available ; - is informed about the study and has provided Informed Consent as applicable. Exclusion Criteria: - Patient with proximal humeral fracture, - previous history of infection, - rotator cuff tear, cuff tear arthropathy, - significant bone loss of the glenoid (more than 25% of the articular surface), - nerve palsy, - revision arthroplasty.

Additional Information

Official title An Observational Cohort Study Evaluating the Safety and Performance of Aequalis Resurfacing Head Implant in a Consecutive Series of Patients With Shoulder Arthroplasty
Principal investigator Lionel NEYTON, MD
Description Resurfacing head implants allow restoring of the normal joint mechanics and stability of the shoulder with minimal bone resection and low peripheral fracture risk, while preserving humeral bone stock. Non cemented head implants also allow for an easy re-intervention if needed. The success of resurfacing implants largely depends on the etiology, with the best results in primary shoulder arthrosis, and the worst in post-traumatic and cuff-tear arthropathy. The Aequalis® Resurfacing Humeral Head is designed to restore the humeral head. It shares the same indications as shoulder arthroplasty in general, including the various types of arthritis and conditions resulting in loss of joint cartilage, joint incongruity, pain, and stiffness. Resurfacing humeral head implants allow minimal bone resection while preserving humeral bone stock as compared to standard anatomic humeral implants. However, few data are available on mid-term effects of the resurfacing head implant developed by Tornier. This Post-Marketing study is implemented for the Aequalis® Resurfacing Head in shoulder arthroplasty to collect medium and long-term clinical data on performance and safety. It is designed to collect data from consecutive series in European patients for at least 12 months of follow-up and up to 10 years. If possible, the study duration and collection of information will be prolonged. Further follow-up can be implemented, by amendments.
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Tornier.